Last reviewed · How we verify

Poractant Alfa Intratracheal Suspension [Curosurf]

Hospital Clinic of Barcelona · Phase 3 active Small molecule

Poractant Alfa Intratracheal Suspension [Curosurf] is a Surfactant replacement therapy Small molecule drug developed by Hospital Clinic of Barcelona. It is currently in Phase 3 development for Respiratory distress syndrome in premature infants. Also known as: Curosurf®, Surfactant endotracheal administration following a recruitment HFOV manoeuvre.

Poractant alfa is a surfactant replacement therapy that helps to reduce the surface tension in the lungs, facilitating easier breathing.

Poractant alfa is a surfactant replacement therapy that helps to reduce the surface tension in the lungs, facilitating easier breathing. Used for Respiratory distress syndrome in premature infants.

At a glance

Generic namePoractant Alfa Intratracheal Suspension [Curosurf]
Also known asCurosurf®, Surfactant endotracheal administration following a recruitment HFOV manoeuvre
SponsorHospital Clinic of Barcelona
Drug classSurfactant replacement therapy
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Surfactant is a naturally occurring substance in the lungs that helps to reduce the surface tension of water, making it easier to breathe. Poractant alfa is a synthetic version of this substance, which is administered intratracheally to help improve lung function in premature infants with respiratory distress syndrome.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Poractant Alfa Intratracheal Suspension [Curosurf]

What is Poractant Alfa Intratracheal Suspension [Curosurf]?

Poractant Alfa Intratracheal Suspension [Curosurf] is a Surfactant replacement therapy drug developed by Hospital Clinic of Barcelona, indicated for Respiratory distress syndrome in premature infants.

How does Poractant Alfa Intratracheal Suspension [Curosurf] work?

Poractant alfa is a surfactant replacement therapy that helps to reduce the surface tension in the lungs, facilitating easier breathing.

What is Poractant Alfa Intratracheal Suspension [Curosurf] used for?

Poractant Alfa Intratracheal Suspension [Curosurf] is indicated for Respiratory distress syndrome in premature infants.

Who makes Poractant Alfa Intratracheal Suspension [Curosurf]?

Poractant Alfa Intratracheal Suspension [Curosurf] is developed by Hospital Clinic of Barcelona (see full Hospital Clinic of Barcelona pipeline at /company/hospital-clinic-of-barcelona).

Is Poractant Alfa Intratracheal Suspension [Curosurf] also known as anything else?

Poractant Alfa Intratracheal Suspension [Curosurf] is also known as Curosurf®, Surfactant endotracheal administration following a recruitment HFOV manoeuvre.

What drug class is Poractant Alfa Intratracheal Suspension [Curosurf] in?

Poractant Alfa Intratracheal Suspension [Curosurf] belongs to the Surfactant replacement therapy class. See all Surfactant replacement therapy drugs at /class/surfactant-replacement-therapy.

What development phase is Poractant Alfa Intratracheal Suspension [Curosurf] in?

Poractant Alfa Intratracheal Suspension [Curosurf] is in Phase 3.

What are the side effects of Poractant Alfa Intratracheal Suspension [Curosurf]?

Common side effects of Poractant Alfa Intratracheal Suspension [Curosurf] include Apnea, Pneumothorax, Bronchopulmonary dysplasia.

Related